Bristol Myers Squibb (CELG-RI) Gains from Sales and Divestitures (2011 - 2012)
Bristol Myers Squibb (CELG-RI) reported Gains from Sales and Divestitures of -$3.3 million for Q4 2012, up 1.74% year-over-year from -$3.3 million in Q1 2012, and up 1.74% quarter-over-quarter from -$3.4 million in Q4 2011.
Bristol Myers Squibb (CELG-RI) Gains from Sales and Divestitures (2011 - 2012) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 2 years of Gains from Sales and Divestitures data on file, last reported at -$3.3 million in Q4 2012.
- Gains from Sales and Divestitures for Q4 2012 came in at -$3.3 million, up 1.74% year-over-year; the trailing twelve-month figure through Dec 2012 was -$3.3 million (up 1.74% YoY), and the FY2012 annual result was -$3.3 million, up 1.74% from the prior year.
- Gains from Sales and Divestitures rose to -$3.3 million in Q4 2012 per CELG-RI's latest filing, from -$3.4 million in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at -$3.3 million in Q4 2012 and troughed at -$3.4 million in Q4 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | -3.34 Mn |
| Dec 31, 2012 | -3.34 Mn |
| Dec 31, 2011 | -3.40 Mn |
| Dec 31, 2011 | -3.40 Mn |